

Docket No.: 2294-0122PUS1
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Alfonso ROMERO et al.

Application No.: 10/594,004

Confirmation No.: 8959

Filed: September 25, 2006

Art Unit: 1616

For: PROLONGED-RELEASE COMPOSITIONS
COMPRISING TORASEMIDE AND A
MATRIX-FORMING POLYMER

Examiner: A. L. Fisher

DECLARATION SUBMITTED UNDER 37 C.F.R. § 1.132

Honorable Commissioner
Of Patents and Trademarks
P.O. Box 1450
Alexandria, VA 22313-1450

September 3, 2010

Sir:

I, Dr. Antonio Guglietta of the Pharmaceutical Research and Development Center, Ferrer Internacional, S.A., Spain, do hereby declare the following:

I have attached a copy of my curriculum vitae to this Declaration.

I am the Research and Development Director and have worked in this field for over ten years.

I am familiar with the above referenced patent application and the area of science dealing with prolonged release compositions.

I have read and understand the subject matter of the Office Action of March 17, 2010.

The following comments are offered in support of the patentability of the instant invention.

The Examiner seems to believe that a skilled artisan would find the invention of Application No. 10/594,004 obvious because of the following references: Maegerlein et al., Azarmi et al., Pankhania et al., Berner et al. and Kaplan. I disagree.

In particular, lactose is a well known diluent which is normally used in immediate release formulation, not in controlled release formulations since it normally does not influence or control the release profile. On the contrary, it is sometimes used as a release enhancer. Scientists working in the controlled-release area would not have reasonably expected success in obtaining a controlled release formulation by using lactose.

To assist the Examiner in appreciating the instant invention, Applicants make the following points. The present invention has a formulation containing torasemide, a matrix forming polymer and lactose as the main diluent. This results in a prolonged-release formulation of torasemide which shows a kinetic profile with fewer fluctuations and steadier levels. The percentage of lactose in the preferred formulations of the invention is about 50% of the blend (see examples 6-9). On the other hand, the matrix forming polymer is present in a small proportion in the formulation of the invention; normally less than 20% of the total composition, and more preferably from 2-5%.

To illustrate the kinetic profiles of examples of the torasemide formulations (tablets) of the claimed invention, Meyprogat[®] 90 (i.e. guar gum) at 10, 5 and 3% of the total tablet weight was tested as shown in the Table below for the 5 mg tablet dose (5 mg torasemide).

Formulation	T1604	T1704	T1804
Torasemide	5.9 %	5.9 %	5.9 %
Corn starch	36.2 %	36.2 %	36.2 %
Colloidal Silicon Dioxide	0.5 %	0.5 %	0.5 %
Meyprogat[®] 90	10.0%	5.0 %	3.0 %
Magnesium stearate	0.3 %	0.3 %	0.3 %
Lactose	47.1%	52.1 %	54.1 %

The following dissolution tests were performed with hydrochloric acid 0.1 N.

In comparison with Sutril[®] (Immediate release formulation), the experimental tablets showed a prolonged release behaviour starting from 3% of guar gum (batch T1804). The total

release of the active in this batch (T1804) was produced in 5 hours. Batches with 5% and 10% of the excipient (i.e. T1704 and T1604) presented a 75% active release within 5 hours with a similar kinetic profile. The following table and figure show the results of the kinetic profile of these formulations.

	Sutril 5 mg		Batch T1604		Batch T1704		Batch T1804	
Time (min)	Release per time fraction %	Release %	Release per time fraction %	Release %	Release per time fraction %	Release %	Release per time fraction %	Release %
0	-	0	-	0	-	0	-	0
0.5	98.2	98.2	22.5	22.5	23.4	23.4	26.6	26.6
1	2.3	100.5	10.2	32.7	7.2	30.6	7.4	34.1
2	0.4	101.3	7.5	47.7	6.4	43.5	12.7	59.6
3	-0.6	100.1	5.7	59.0	5.7	54.8	12.8	85.1
4	-0.3	98.9	3.7	73.9	6.1	79.1	3.1	97.5

Table. Release values (with HCl 0.1N) for tablets manufactured with Meyprogat[®] 90.




Figure. Release profiles (with HCl 0.1N) of Torasemide from Meyprogat[®] 90 matrix tablets.

The percentage of lactose in the experiments is above 45% with respect of the blend.
The amount of guar gum is less than 10% of the amount of lactose.

Therefore, it is my opinion that the invention as described in the current claims would not have been obvious to a skilled artisan in view of the cited references. Neither do I believe that a skilled artisan would have had a reasonable expectation of success if they had tried to combine the cited references in order to obtain the instant invention.

The undersigned hereby declares that all statements made herein based upon knowledge are true, and that all statements made based upon information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

DATED: September 3, 2010



Dr. Antonio Guglietta

Curriculum Vitae:
Antonio Guglietta, MD, PhD
(Updated Jul 2010)



Personal

Place of Birth Sperlonga (LT), Italy

Date of Birth March, 8 1956

Citizenship Italy

Languages Italian (fluent)
 English (fluent)
 Spanish (fluent)
 Catalan (basic)
 French (basic)

Address Grupo Ferrer Reserach Center
 Juan de Sada 32
 08028 Barcelona
 Spain
 Tel. ++ 34 (93) 509-3206 (business)
 Fax ++ 34 (93) 411-2764
 E-mail: guglietta-research@ferrergrupo.com (business)
 E-mail: antonioguglietta@ureach.com (home)

Education

1982: University "La Sapienza", Rome, Italy
 M.D. degree (graduated with honors)
*Thesis: Synthetic peptides related to the Dermorphins:
 Synthesis and biological activities of the shorter homologues
 and of analogues of the heptapeptides*

1988: University "La Sapienza" , Rome, Italy
 Ph.D. (Gastroenterology: graduated with honors)
*Thesis: Central nervous regulation of gastric acid secretion.
 Role of Bombesin, Dermorphin and Calcitonin*

1999 Management Development Program
 University of Michigan, Business School
 Ann Arbor, MI, USA

2010: University of Navarra IESE Business School:
Executive Development Programa (PDD)

Curriculum Vitae - Antonio Guglietta, MD, PhD (cont.)

Residency and internships

1982	Resident Hospital "Umberto I", Rome, Italy (Surgery)
1982	Resident Hospital "Dono Svizzero", Formia, Italy (Gynecology and Obstetrics)
1982	Resident Hospital "Umberto I", Rome, Italy (Internal medicine)
1983	Internship Hospital "Nuovo Regina Margherita", Rome, Italy (Gastroenterology)
1983	Internship Hospital "San Gallicano", Rome, Italy (Dermatology & Venerology)

Board Certification

1982	Italian Board Certification
-------------	-----------------------------

Post graduate training

1991	Gastrointestinal pharmacology American Gastroenterological Association New Orleans, LA, USA
1993	Mucosal diseases of the gastrointestinal tract American Gastroenterological Association Boston, MA, USA
1993	Gastrointestinal endoscopy European Society of Gastrointestinal Endoscopy Barcelona, Spain
1994	Clinical Immunology in gastroenterology and hepatology American Gastrointestinal Association New Orleans, LA, USA

Curriculum Vitae – Antonio Guglietta, MD, PhD (cont.)

1995

Evolving Concepts in Gastrointestinal and Liver Diseases
American Gastrointestinal Association
San Diego, CA, USA

Curriculum Vitae – Antonio Guglietta, MD, PhD (cont)

Professional Organizations

1986 -	American Society for Neuroscience
1986 -	International Brain Research Organization (IBRO)
1987 -	American Association for the Advancement of Science
1987 -	New York Academy of Science
1988 -	American Endocrine Society
1988 -1991	North Carolina Society for Neuroscience
1991 -	American Gastroenterological Society
1992 -	International Brain-Gut Society
1994-	International Union of Pharmacology - GI Section
1995 -	Gastroenterology Research Group
1996 -	Worldwide Hungarian Medical Academy

Scientific Offices held

May 1996-July 1998	Member of the Communications Committee of International Union of Pharmacology (IUPHAR) - GI Section
July 1998-July 2002	Secretary of the International Union of Pharmacology (IUPHAR) – GI Section
Oct 1996-July 2000	Secretary of the International Brain-Gut Society
1995-Date	Founder and President of " <i>International Researchers in Gastroenterology & Hepatology</i> " a non-profit organization devoted to foster scientific interactions among investigators working in the area of gastroenterology and hepatology around the world.

Manuscript and grants review activity

- Gastroenterology
- British J. Pharmacology
- Eur. Journal Pharmacology
- J. Pharm. Exp. Ther.
- Can. J. Physiol. Pharmacol.
- Life Sciences
- VA grant reviewer
- Am. J. Physiology

Curriculum Vitae – Antonio Guglietta, MD, PhD (cont.)

Positions

1980-1982	Intern, Institute of Medical Pharmacology, University "La Sapienza", Rome, Italy
1982-1984	Post doctoral Fellow Institute of Medical Pharmacology, University "La Sapienza", Rome, Italy
1984-1987	Visiting Fellow, Peptide Neurochemistry Group National Institute of Environmental Health Sciences Research Triangle Park, N.C., USA
1987-1988	Visiting Associate Peptide Neurochemistry Group National Institute of Environmental Health Sciences Research Triangle Park, N.C., USA
1988-1990	Visiting Scientist Clinical Biochemistry Dept. of Biochemistry Glaxo Research Laboratories Research Triangle Park, NC, USA
1990-1991	Visiting Scientist Immunopathology Dept. of Therapeutics Parke-Davis Pharmaceutical Research Division of Warner-Lambert Company Ann Arbor, MI, USA
1991-1992	Research Associate Immunopathology Dept. of Therapeutics Parke-Davis Pharmaceutical Research Division of Warner-Lambert Company Ann Arbor, MI, USA
1992- 2000	Senior Research Associate Immunopathology Dept. of Therapeutics Parke-Davis Pharmaceutical Research Division of Warner-Lambert Company Ann Arbor, MI, USA
2000- Date	R&D Director Grupo Ferrer Internacional Barcelona, Spain

Curriculum Vitae – Antonio Guglietta, MD, PhD (cont.)

Awards

1984-1987	Visiting Fellowship the Fogarty International Center, National Institutes of Health, Bethesda, Maryland, U.S.A.
1986	Travel Grant provided by the Endocrine Society for the purpose of attending the 68 th Annual Meeting of the Endocrine Society.
1988	Grant provided by the Organizing Committee of International Conference on Gastroenteric Biology for the purpose of attending such Conference
1991-1997	Name included in: Who's Who in Science and Engineering, 1st Ed. 1991, 2 nd Ed. 1994-1995, 3 rd Ed. 1996-1997. Marquis Who's Who.
1992-1994	Name included in: Who's Who in America, 47th edition. 1992, 48 th Edition 1994. Marquis Who's who.
1994-1998	Name included in : Who's Who in the Midwest. 24th edition. 1994, 25 th Ed. 1996, 26 th Ed. 1998, Marquis Who's who
1994	International Men of the Year in recognition of his services to Research Published by International Biographical Centre, Cambridge, England
1995-1996	Name included in : Who's Who in the world, 12th edition. Marquis Who's who 1995-1996.
1997-1998	Name included in Who's Who in Medicine and Health care, 1st Ed. Marquis Who's Who. 1997-1998

Curriculum Vitae – Antonio Guglietta, MD, PhD (cont.)

Selected invited lectures

- Jun. 1989** 3rd International congress of Videoendoscopy
Abano Terme, Italy
Title of the presentation:
Quantitative endoscopy: evaluation of ulcer re-epithelization
- Jun. 1992** 3rd International symposium on experimental ulcer disease: "Stress, Basic and Clinical Research; Gastrointestinal Protection, Zagreb, Croatia
Title of the presentation:
Possible clinical use of peptide growth factors in the GI tract: perspectives and obstacles
- Nov. 1994** 5th International symposium on GI research: Zagreb, Croatia.
Title of the presentation:
Preclinical evaluation of compounds with possible therapeutic activity in inflammatory bowel disease
- May 1995** University of California San Diego
Cancer Center
San Diego, CA, USA
Title of presentation:
Activity of EGF in the GI tract: Preclinical and clinical data
- June 1996** IBC meeting on IBD
Philadelphia, PA USA
Title of presentation:
Activity of EGF in animal models of IBD
- Apr 1997** University of Bologna, Italy
Institute of Hematology
Title of presentation:
"Can we protect the GI tract from chemiotherapies-induced damage in hematologic patients ? Role of EGF"
- Apr. 1997** University of Padua, Italy
Institute of Internal Medicine
Title of presentation:
" New strategies for the pharmacotherapy of inflammatory gastrointestinal diseases"

Curriculum Vitae - Antonio Guglietta, MD, PhD (cont.)

Bibliography

1. De Castiglione R., Faoro F., Perseo G., Piani S., Santangelo F., Melchiorri P., Falconieri Erspamer G., Erspamer V., **Guglietta, A.**
SYNTHETIC PEPTIDES RELATED TO DERMORPHIN. I. SYNTHESIS AND BIOLOGICAL ACTIVITIES OF THE SHORTER HOMOLOGUES AND ANALOGUES OF THE HEPTAPEPTIDE.
Peptides 2:265-269, 1981.
2. Melchiorri P., Falconieri Erspamer G., Erspamer V., **Guglietta, A.**, De Castiglione R., Faoro F., Perseo G., Piani S., Santangelo F.
SYNTHETIC PEPTIDES RELATED TO DERMORPHIN. II. SYNTHESIS AND BIOLOGICAL ACTIVITIES OF NEW ANALOGUES.
Peptides 3:745-748, 1982.
3. **Guglietta, A.**, Strunk C.L., Irons B.J., Lazarus L.H.
CENTRAL NEUROMODULATION OF GASTRIC ACID SECRETION BY BOMBESIN-LIKE PEPTIDES.
Peptides 6 (Suppl. 3):75-81, 1985.
4. Lazarus L.H., Wilson W.E., Gaudino G., Irons B.J., **Guglietta, A.**
EVOLUTIONARY RELATIONSHIP BETWEEN NON MAMMILIAN AND MAMMILIAN PEPTIDES.
Peptides 6 (Suppl. 3): 295-307, 1985.
5. Improta G., **Guglietta, A.**
THE ROLE OF CAUDATE NUCLEUS IN DERMORPHIN-INDUCED CATALEPSY IN RATS.
Peptides 6 (Suppl. 3): 161-164, 1985.
6. **Guglietta, A.**, Irons B.J., Lazarus L.H., Melchiorri P.
STRUCTURE-ACTIVITY RELATIONSHIP OF DERMORPHIN ON GASTRIC SECRETION.
Endocrinology 120 (5):2137-2147, 1987.
7. **Guglietta, A.**, Irons B.J., Lazarus L.H.
INTERACTION BETWEEN BOMBESIN AND PROSTAGLANDINS IN THE CONTROL OF GASTRIC SECRETION.
Ann. New York Acad. Sci. 547: 486-487, 1988

Curriculum Vitae - Antonio Guglietta, MD, PhD (cont.)

8. Lazarus L.H., **Guglietta, A.**, Wilson W.E.,
Grimes L.M., Irons B.J. and Yajima H.
NEUROMEDIN B: PHYSIOLOGICAL AND PHARMACOLOGICAL
PERTUBATIONS.
Ann. New York Acad. Sci. 547: 404-414, 1988
9. Lazarus L.H., Irons B.J., Grimes L.M., Wilson W.E.,
Guglietta, A., Yajima H.
ASSESSMENT OF NEUROMEDIN B POLYCLONAL ANTIBODIES AS
MOLECULAR PROBE IN NEURAL TISSUE.
J. Neurol. Methods 23: 161-172, 1988
10. **Guglietta, A.**, Irons B.J., Lazarus L.H.
EFFECT OF BOMBESIN, DERMORPHIN AND SALMON CALCITONIN ON
GASTRIC ACID SECRETION IN RATS.
Meth. Find. Exp. Clin. Pharmacol. 10 (8):481-485, 1988
11. **Guglietta, A.**, Irons B.J., Lazarus L.H.
EFFECT AND MECHANISM OF ACTION OF LITHIUM CHLORIDE ON
GASTRIC ACID SECRETION.
Gastroenterology 95: 1454-1459, 1988
12. **Guglietta, A.**
Regolazione Nervosa Della Secrezione
Acida Gastrica: Ruolo Della Bombesina, Dermorfina e
Calcitonina.
Doctoral Thesis. Ph.D. program in Gastroenterology,
University of Rome", La Sapienza ", Italy, July 1988.
13. Lazarus, L.H., **Guglietta, A.**, Wilson, W.E., Irons, B.J.,
de Castiglione R.
DIMERIC DERMORPHIN ANALOGUES AS MU-RECEPTOR PROBES ON RAT
BRAIN MEMBRANES. CORRELATION BETWEEN CENTRAL MU-RECEPTOR POTENCY AND
SUPPRESSION OF GASTRIC ACID SECRETION
Journal Biological Chemistry 264 (1): 354-362, 1989
14. Lazarus, L.H., Wilson, W.E., de Castiglione, R.,
Guglietta, A.
DERMORPHIN GENE SEQUENCE PEPTIDE WITH HIGH AFFINITY AND
SELECTIVITY FOR DELTA OPIOID RECEPTORS.
Journal Biological Chemistry 264 (6): 3047-3050, 1989.
15. **Guglietta, A.**, Irons, B.J., Lazarus, L.H., de
Castiglione, R., Melchiorri, P.
DIMERIC DERMORPHIN PEPTIDES: CENTRAL ADMINISTRATION
SUPPRESSES GASTRIC ACID SECRETION THROUGH
INTERACTION WITH MU-TYPE OPIOID RECEPTOR
Meth. Findings Exp. Cli. Pharmacol.
11 (11): 663-670, 1989.

Curriculum Vitae - Antonio Guglietta, MD, PhD (cont.)

16. **Guglietta, A.**, Nardi, R.V. and Lazarus L.H.
INDOMETHACIN (i.c.v.) REVERSES THE INHIBITORY ACTION
OF PEPTIDES ON GASTRIC SECRETION.
European J. Pharmacology 170 (1-2): 87-90, 1989.
17. Lazarus, L.H., Wilson, W.E., **Guglietta, A.** and de
Castiglione R.
DERMORPHIN INTERACTION WITH RAT BRAIN OPIOID RECEPTORS:
INVOLVEMENT OF HYDROPHOBIC SITES IN THE BINDING DOMAIN.
J. Molecular Pharmacol. 37: 886-892 1990.
18. **Guglietta, A.**, Hervada, T. and Nardi, R.V.
COMPUTER-BASED QUANTITATIVE MORPHOMETRIC ANALYSIS OF THE
DYNAMIC CHARACTERISTICS OF INDOMETHACIN AND EtOH-INDUCED
GASTRIC LESIONS IN THE RAT.
J. Pharmacological Methods.24: 73-78 1990
19. **Guglietta, A.**, Hervada, T. and Nardi, R.V.
THE USE OF A THYMIDINE INCORPORATION ASSAY IN THE
EVALUATION OF THE HEALING PROCESS FOLLOWING ETHANOL OR
INDOMETHACIN-INDUCED GASTRIC DAMAGE IN RATS.
Meth. Find. Exp. Cli. Pharmacol. Vol. 12 N. 3, 1990.
20. **Guglietta, A.**, Hervada, T. and Nardi, R.V. and Lesch CA.
EFFECT OF PLATELET-DERIVED GROWTH FACTOR-BB ON INDOMETHACIN-INDUCED
GASTRIC LESIONS IN RATS.
Scan. J. Gastroenterol.: 27: 673-676, 1992.
21. **Guglietta, A.**
POSSIBLE CLINICAL USE OF PEPTIDE GROWTH FACTORS IN THE GI TRACT:
PERSPECTIVES AND OBSTACLES.
Exp. and Clinical Gastroenterology: Vol 3, N. 1, pp. 1-6, 1993.
22. **Guglietta A.**, and Lesch CA. EFFECT OF h-EGF AND h-EGF 1-48 ON HISTAMINE-
STIMULATED GASTRIC ACID SECRETION IN RATS AND MONKEYS
J. of Physiology (Paris): 1993: 87. 343-347.
23. **A. Guglietta**, CA Lesch, M. Romano, C., RW McClure, and RJ Coffey.
EFFECT OF TRANSFORMING GROWTH FACTOR ON GASTRIC ACID SECRETION IN RATS
AND MONKEYS.
Dig. Dis. Sci.: 1994: 39(1), 177-182.
24. M. Veljaca, CA Lesch, R. Pillana, B. Sanchez, K. Chan, **A. Guglietta**
BPC-15 REDUCES AGAINST TRINITROBENZENE SULFONIC ACID-INDUCED
COLONIC DAMAGE IN RATS.
J. Pharmacol. Exp. Therap.: 1995: 272(1), 417-422.
25. **A. Guglietta**, PB Sullivan.
CLINICAL APPLICATIONS OF EPIDERMAL GROWTH FACTOR
Eur. J. Gastroenterology and Hepatology 1995: 7: 945-950

Curriculum Vitae - Antonio Guglietta, MD, PhD (cont.)

26. M. Romano, CA Lesch, KS Meise, M. Veljaca, B. Sanchez, ER Kraus, R. Boland, **A. Guglietta**, RJ Coffey
INCREASED GASTRODUODENAL CONCENTRATION OF TRANSFORMING GROWTH FACTOR α IN ADAPTATION TO ASPIRIN IN MONKEYS AND RATS.
Gastroenterology 110 (5): 1446-1455, 1996
27. Sizemore, N., Dudeck, RC., Barksdale, CM., Nordblom, GD., Mueller, WT., McConnel P., Wright, DS., **Guglietta, A.**, Kuo, BS.
DEVELOPMENT AND VALIDATION OF TWO SEPARATE ENZYME IMMUNOASSAYS (ELISA) FOR QUANTITATION OF HUMAN EPIDERMAL GROWTH FACTORS (hEGFS).
Pharmaceutical Res. 13: 1088-1094, 1996
28. S. Seiwert, **A. Guglietta**, L. Pecur, Z. Grabarevic, S., Djacic, Z. Hutinec
IMMUNOISTOCHEMICAL TESTING OF A NEW ANTI-EGF ANTIBODY
Folia Histochemica et Cytobiologica.: 34:27-29, 1996
29. V.M. Baragi, L. Qiu, Z. Gunja-Smith, J. F. Woessner Jr, C.A. Lesch, **A. Guglietta**
ROLE OF METALLOPROTEINASES IN THE DEVELOPMENT AND HEALING OF ACETIC ACID-INDUCED GASTRIC ULCER IN RATS.
Scand. J. Gastroenterol.: 32:419-426, 1997
30. Dyer RD, Bornemeier D., Doubleday R, Song Y., **Guglietta A.**
Laemont K., Okonkwo G. Schrier D.
A NOVEL CLASS OF SLOW-EQUILIBRATING, ORALLY ACTIVE PGHS-2 INHIBITORS.
Inflammation Res.
31. J.B. Epstein, S. Emerton, **A. Guglietta**, N. Le.
ASSESSMENT OF EPIDERMAL GROWTH FACTOR IN ORAL SECRETIONS OF PATIENTS RECEIVING RADIATION THERAPY FOR CANCER.
Oral Oncology, 33 (5), 359-363, 1997
32. CA Lesch, RB Gilbertsen, Y. Song, R. Dyer, D. Schrier, ER Kraus, B. Sanchez, **A. Guglietta**
EFFECT OF NOVEL ANTI-INFLAMMATORY COMPOUNDS ON HEALING OF ACETIC ACID INDUCED GASTRIC ULCER IN RATS
JPET 287 (1), 301-306, 1998
33. CA Lesch, ER Kraus, B. Sanchez, RB Gilbertsen, A., **Guglietta. A.**
LACKS OF BENEFICIAL EFFECT OF PGHS-2 INHIBITORS IN AN EXPERIMENTAL MODEL OF COLITIS
Methods and Finding in Exp and Clin Pharmacol. 21 (2), 99-104, 1999
34. Song, Y. Connor DT., Doubleday R., Sorenson RJ, Sercel AD, Unangst PC, Tobias, B., Roth B., Gilbertsen RB, Chan K., Schrier DJ, Laemont K., Okonkwo GC., **Guglietta A.**, Bornemeier DA., Dyer RD.
SYNTHESIS, STRUCTURE-ACTIVITY RELATIONSHIPS AND IN-VIVO EVALUATION OF SUBSTITUTED DI-T-BUTYLPHENOL AS A NOVEL CLASS OF POTENT SELECTIVE AND ORALLY ACTIVE PGHS-2 INHIBITORS, 1. THIAZOLONE AND OXAZOLONE SERIES.
J. Medicinal Chemistry 42 (7), 1151-1160, 1999

Curriculum Vitae - Antonio Guglietta, MD, PhD (cont.)

35. Song Y., Connor DT, Sercel AD, Sorenson RJ, Doubleday R, Unangst PC, Roth BD, Beylin VG, Gilbertsen RB, Chan K, Schrier DJ, **Guglietta A**, Bornemeir DA, Dyer RD.
SYNTHESIS, STRUCTURE-ACTIVITY RELATIONSHIPS AND IN-VIVO EVALUATION OF
SUBSTITUTED DI-T-BUTYLPHENOL AS A NOVEL CLASS OF POTENT SELECTIVE AND ORALLY
ACTIVE PGHS-2 INHIBITORS, 2. 1,3,4- AND 1,2,4-THIAZOLONE SERIES.
J. Medicinal Chemistry 42 (7), 1161-1169, 1999

36. CA. Lesch, ER Kraus, **A. Guglietta**
3-ISOBUTYL GABA PROTECTS AGAINST EXPERIMENTALLY INDUCED DAMAGE IN THE UPPER
GASTROINTESTINAL TRACT BY A CENTRALLY MEDIATED MECHANISM OF ACTION
Journal of Digestive Protection 1 (2), 57-64, 2000

37. Epstein, JB, Gorsky M, **Guglietta A**, Le N., Sonis, S.
THE CORRELATION BETWEEN EPIDERMAL GROWTH FACTOR LEVELS IN SALIVA AND THE
SEVERITY OF ORAL MUCOSITIS DURING OROPHARYNGEAL RADIATION THERAPY
Cancer: 89 (11): 2258-65, 2000

38. Palacin, C. Tarrago C, Agut J. **A. Guglietta.**
IN VITRO ACTIVITY OF SERTACONAZOL, FLUCONAZOL, KETOCONAZOL, DENTICONAZOLE,
CLOTRIMAZOL AND ITRACONAZOLE AGAINST PATHOGENIC VAGINAL YEAST ISOLATES.
Meth. & Find Exp Clin Pharmacol 23 (2): 61-64, 2001

39. J. Bolos, M. Princep, **A. Guglietta**
ABAPERIDONE HYDROCHLORIDE
Drugs of the Future 26 (4), 335-341, 2001

40. AJ Carrillo-Munoz, S. Brio, G. Quindos, C. Palacin, **A. Guglietta**, A. Espinel-Ingroff
SERTACONAZOLE: IN-VITRO ANTIFUNGAL ACTIVITY AGAINST VAGINAL AND OTHER
SUPERFICIAL YEAST ISOLATES
J. Chemother. 13(5): 555-62, 2001

41. Lirussi, F. **A. Guglietta**
IMPAIRED NATURAL KILLER CELL CYTOTOXIC ACTIVITY IN CHRONIC HEPATITIS C VIRAL
INFECTION: A CONTROLLED STUDY
Current Therapeutic Research

42. M. Guerrero, C. Albet, A. Palomer, **A. Guglietta**
DRYING IN PHARMACEUTICAL AND BIOTECHNOLOGICAL INDUSTRIES
Food Science and Technology International: Vol. 9 (3), 237-243, 2003

Curriculum Vitae - Antonio Guglietta, MD, PhD (cont.)

43. Improta G, Carpino F, Petrozza V, **Guglietta A**, Tabacco A, Broccardo M.
CENTRAL EFFECTS OF SELECTIVE NK(1) AND NK(3) TACHYKININ RECEPTOR AGONISTS ON
TWO MODELS OF EXPERIMENTALLY-INDUCED COLITIS IN RATS.
Peptides: Vol. 24 (6), 903-911, 2003
44. Tarragó, C. Alemany, C., Palacin, C., Terencio, J., **Guglietta, A.**
NOVES TECNOLOGIES EN LA RECERCA D'ANTIMICROBIANS
Antimicrobians 55, 67-80, 2004
45. Carrillo-Munoz, A.J., **Guglietta, A.**, Palacín, C., Casals, J., Del Valle, O., Guardia, C.,
Rodriguez, V., Quindos, G.
IN VITRO ANTIFUNGAL ACTIVITY OF SERTACONAZOLE COMPARED WITH NINE OTHER DRUGS
AGAINST 250 CLINICAL ISOLATES OF DERMATOPHYTES AND SCOPULARIOPSIS BREVICAULIS.
Chemotherapy 50 (6), 308-313, 2004
46. Falcó J.L., Lloveras M., Buira I., Teixidó J., Borrell J.I., Terencio J., Palomar A., **Guglietta A.**
DESIGN, SYNTHESIS AND BIOLOGICAL ACTIVITY OF ACYL SUBSTITUTED 3-AMINO-5-METHYL-
1,4,5,7-TETRAHYDROPYRAZOLO [3,4-b]PYRIDIN-6-ONES AS POTENTIAL HYPNOTIC DRUGS.
Eur. J. Med. Chem. 40, 1179-1187, 2005
47. Falcó, J.L., Piqué, M., González, M., Buira, I., Méndez E., Terencio, J., Pérez, C., Princep, M.,
Palomer, A., **Guglietta, A.**
SYNTHESIS, PHARMACOLOGY AND MOLECULAR MODELING OF N-SUBSTITUTES 2-PHENYL-
INDOLES AND BENZIMIDAZOLES AS POTENT GABA_A AGONISTS
Eur. J. Med. Chem. 41, 985-990, 2006
48. Contelles, J.M., León, R., De los Rios, C., **Guglietta, A.**, Terencio, J., López M.G., García,
A.G., Villarroya, M.
NOVEL MULTIPOTENT TACRINE-DIHYDROPYRIDINE HYBRIDS, WITH IMPROVED
ACETYLCHOLINESTERASE INHIBITORY AND NEUROPROTECTIVE ACTIVITIES, AS POTENTIAL
DRUGS FOR THE TREATMENT OF ALZHEIMER'S DISEASE.
J. Med. Chem. In press.
49. Falcó, J.L., Plasencia, G., Zamora, I. Piqué, M., González, M., Morató, I., Borrell, I., Teixidó,
J., Terencio, J., Princep, M., Buira, I., Méndez, E., **Guglietta, A.**
SCAFFOLD HOPPING: APPLICATION TO THE DISCOVERY OF NOVEL GABAA RECEPTORS
LIGANDS
Afinidad: submitted Feb 2007
50. Palomer, A., Princep, M., **Guglietta, A.**
RECENT ADVANCES IN THE TREATMENT OF INSOMNIA
Annual Rep. Medicinal Chemistry, 42, 63-80, 2007
51. Sierra, J.M., **Guglietta, A.**
MECHANISMS OF LINEZOLID RESISTANCE
Antimicrob. Agents and Chemother. Submitted

52. A. Roca-Cusachs, J. Aracil-Vilar, C. Calvo-Gómez, J.V. Vaquer-Pérez, F. Laporta-Crespo, M.J. Rojas-Serrano, **A. Guglietta**
CLINICAL EFFECTS OF TORASEMIDE PROLONGED RELEASE IN MILD TO MODERATE HYPERTENSION: A RANDOMIZED MOM-INFERIORITY TRIAL VERSUS TORASEMIDE IMMEDIATE RELEASE.
J. Clin. Hypertension: Submitted
53. M.J. Barbanoj, M.R. Ballester, R.M. Antonijoan, M. Puentes, S. Gropper, B. Santos, C. Albet, **A. Guglietta**.
A BIOAVAILABILITY/BIOEQUIVALENCE AND PHARMACOKINETIC STUDY OF TWO ORAL DOSES OF TORASEMIDE (5 AND 10 MG) PROLONGED RELEASE VERSUS THE CONVENTIONAL FORMULATION
Clin Exp. Pharmacol & Physiol. 36: 469-477, 2009
54. M.J. Barbanoj, M.R. Ballester, R.M. Antonijoan, I. Gich, P. Pelagio, S. Gropper, B. Santos, **A. Guglietta**.
COMPARISON OF REPEATED-DOSE PHARMACOKINETICS OF PROLONGED RELEASE AND IMMEDIATE RELEASE TORASEMIDE FORMULATIONS IN HEALTHY YOUNG VOLUNTEERS.
Fund. Clin. Pharmacology vol 3 (1) 115-125, 2009-05-20
55. **A. Guglietta**, M. Guerrero
ISSUE TO CONSIDER IN THE PHARMACEUTICAL DEVELOPMENT OF A CARDIOVASCULAR POLYPILL
Nature Clinical Practice Cardiovascular Medicine 6(2): 112-9, 2009
56. C. Palacín, C Tarragó, J. Terencio, B. Santos, N. Martí, D. Palop, M. Delgado, **A. Guglietta**
ARASERTACPNAZOL NITRATE. THE ACTIVE ENANTIOMER OF SERTACONAZOL NITRATE
J. Antimicrob. Agents (Submitted Oct. 2008)
57. JI Falcó, M. González, M. Piqué, G. Plasencia, I. Zamora, I. Buira, E. Mendez, J. Terencio, A. Alcantara, C. Perez, M. Princep, A. Palomer, **A. Guglietta**
SCAFFOLD HOPPING: APPLICATION TO THE DISCOVERY OF NOVEL GABA_A RECEPTOR LIGANDS
J. Med. Chemistry (to be submitted Q4-2008)
58. JI Falcó, M. González, M. Piqué, G. Plasencia, I. Zamora, I. Buira, E. Mendez, J. Terencio, A. Alcantara, C. Perez, M. Princep, A. Palomer, **A. Guglietta**
DISCOVERY OF NOVEL IMIDAZOPYRIDAZINES AS POTENT GABA_A RECEPTOR AGONISTS
J. Med. Chemistry (to be submitted Q4-2008)
59. JI Falcó, M. González, M. Piqué, G. Plasencia, I. Zamora, I. Buira, E. Mendez, J. Terencio, A. Alcantara, C. Perez, M. Princep, A. Palomer, **A. Guglietta**
3-ARYL-QUINOLONES: DISCOVERY OF NEW GABAA RECEPTOR LIGANDS
J. Med. Chem (to be submitted Q4-2008)
60. JM Sierra, M. Ortega, C. Tarragó, C. Albet, J. Vila, J. Terencio, **A. Guglietta**
DECREASED LINEZOLID UPTAKE IN AN IN-VITRO SELECTED LINEZOLID RESISTANT STAPHYLOCOCCUS EPIDERMIDIS MUTANT
J. Antimicrob. Chemotherap. Submitted

61. C. Palacín, C. Tarragó, J. Terencio, B. Santos, N. Martí, D. Palop, M. Delgado, **A. Guglietta**
BIOLOGICAL CHARACTERIZATION OF ARASERTACONAZOL NITRATE, THE ACTIVE ENANTIOMER
OF SERTACONAZOL NITRATE
Submitted to Mycosis in Nov, 2009

Curriculum Vitae - Antonio Guglietta, MD, PhD (cont.)

Abstracts

1. Melchiorri, P., **Guglietta, A.**
DERMORPHIN: CENTRAL SITES OF ANALGESIA, CATALEPSY AND
INHIBITION OF GASTRIC SECRETION AND EMPTYING IN RATS.
Fourth International Symposium on
Gastrointestinal Hormones, Stockholm, Sweden, 1982.
Regul. Peptides (S2): 110, 1982
2. **Guglietta, A.**, Strunk, C.L., Irons, B.J. Lazarus, L.H.
CENTRAL NEUROREGULATION OF GASTRIC SECRETION BY
BOMBESIN-LIKE PEPTIDES.
International Symposium on Peptides of non
mammalian origin, Rome, May 11-15, 1985.
3. Lazarus, L.H., Wilson, W.E., Gaudino, G., Irons, B.J.,
Guglietta, A.
EVOLUTIONARY RELATIONSHIP BETWEEN NON MAMMALIAN AND
MAMMALIAN PEPTIDES.
International Symposium on Peptides of non
mammalian origin, Rome, May 11-15, 1985.
4. Improtta, G., **Guglietta, A.**, Melchiorri, P.
THE ROLE OF THE CORPUS STRIATUM AND NUCLEUS ACCUMBENS IN
DERMORPHIN-INDUCED CATALEPSY IN RATS.
International Symposium on Peptides of non
mammalian origin, Rome, May 11-15, 1985.
5. Lazarus, L.H., **Guglietta, A.**, Irons, B.J.,
Melchiorri, P.
NEUROREGULATORY ASPECTS OF DERMORPHIN ANALOGS ON GASTRIC
SECRETION.
68th Annual Meeting of American
Endocrine Society, Anaheim, June 24-27, 1986.
6. **Guglietta, A.**, Irons, B.J., Lazarus, L.H.
POSSIBLE INVOLVEMENT OF PROSTAGLANDINS IN BOMBESIN
NEUROMODULATION OF GASTRIC SECRETION IN RATS.
68th Annual Meeting of American
Endocrine Society, Anaheim, June 24-27, 1986.
7. **Guglietta, A.**, Irons, B.J., Lazarus, L.H., Sivam, S.P.
CENTRAL MECHANISM OF LITHIUM ON THE NEUROREGULATION OF
GASTRIC SECRETION.
26th Annual Meeting of American Society
for Cell Biology, Washington, D.C., Dec. 7-11, 1986.

Curriculum Vitae - Antonio Guglietta, MD, PhD (cont.)

8. **Guglietta, A.**, Irons, B.J., Lazarus, L.H.
COMPARISON BETWEEN BOMBESIN, DERMORPHIN AND CALCITONIN
ON THEIR EFFECT ON GASTRIC SECRETION IN RATS.
69th Annual Meeting of American
Endocrine Society, Indianapolis, June 10-12, 1987.

9. Lazarus, L.H., **Guglietta, A.**, Wilson, W.E.,
Melchiorri, P. de Castiglione, R.
INTERACTION OF DIMERIC DERMORPHIN ANALOGS WITH DELTA AND
MU RECEPTORS ON RAT BRAIN SYNAPTOSOMES.
17th Annual Meeting of the Society for
Neuroscience, New Orleans, November 16-21, 1987.

10. **Guglietta, A.**, Lazarus, L.H., Irons, B.J. and
Melchiorri, P.
ACTIVITY OF DIMERIC DERMORPHIN ANALOGS ON GASTRIC
SECRETION IN THE RAT.
17th Annual Meeting of the Society for
Neuroscience, New Orleans, November 16-21, 1987.

11. **Guglietta, A.**, Irons, B.J., Lazarus, L.H.
INTERACTION BETWEEN BOMBESIN AND BRAIN PROSTAGLANDINS IN
THE CONTROL OF GASTRIC SECRETION.
International Symposium on Bombesin-like
Peptides in Health and Disease, Rome (Italy),
Oct. 13-16, 1987.

12. Lazarus, L.H., **Guglietta, A.**, Wilson, W.E., Irons, B.J.,
Zhao, D., Grimes, L.M., Yajima, H.
NEUROMEDIN b: PHYSIOLOGICAL AND PHARMACOLOGICAL
PERTUBATIONS.
International Symposium on Bombesin-like
Peptides in Health and Disease, Rome (Italy),
Oct. 13-16, 1987.

13. **Guglietta, A.**, Irons, B.J., Lazarus, L.H.
POTENT INHIBITORY EFFECT OF SALMON CALCITONIN ON GASTRIC
ACID SECRETION: ACTION INDEPENDENT OF BRAIN
PROSTAGLANDINS IN RATS.
70th Annual Meeting of American Endocrine
Society, New Orleans, June 8-11, 1988.

14. Lazarus, L.H., **Guglietta, A.**, Wilson, W.E., Irons, B.J.
de Castiglione, R.
SPECIFIC INTERACTION OF DIMERIC DERMORPHIN ANALOGUES
WITH RAT BRAIN MU RECEPTORS: CORRELATION WITH GASTRIC
ACID SECRETION.
70th Annual Meeting of American Endocrine
Society, New Orleans, June 8-11, 1988.

Curriculum Vitae – Antonio Guglietta, MD, PhD (cont.)

15. **Guglietta, A.**, Irons, B.J., Lazarus, L.H.
CENTRAL ADMINISTRATION OF BOMBESIN, DERMORPHIN, AND
CALCITONIN REDUCES THE SEVERITY OF PAF-INDUCED GASTRIC
ULCERS.
18th Annual Meeting of American Society
for Neuroscience, Toronto (Canada), Nov. 13-18, 1988.
16. **Guglietta, A.**, Irons, B.J., Lazarus, L.H.
EFFECT OF CENTRAL ADMINISTERED DIMERIC DERMORPHIN
ANALOGS ON GASTRIC ACID SECRETION AND OPIOID RECEPTOR
STIMULATION IN RATS.
International Conference on Gastroenteric
Biology, Oxnard, CA, (U.S.A.), Oct. 25-28, 1988.
17. Lazarus, L.H., de Castiglione, R., **Guglietta, A.**,
Wilson, W. E.
DERMORPHIN GENE-ASSOCIATED PEPTIDE (DGAP) IS A SELECTIVE
DELTA OPIOID RECEPTOR AGONIST.
Annual Meeting of American Society for
Cell Biology and American Society Biochemistry and
Molecular Biology (Joint Meeting),
San Francisco, CA, (U.S.A.), Jan 29-Feb 2, 1989.
18. Nardi, R.V., **Guglietta, A.**, De Pretis, G., Korman, L.Y.,
Benjamin, S.B. and Loats, H.
QUANTITATIVE ENDOSCOPY: EVALUATION OF ULCER RE-
EPITHELIALIZATION
3rd International Congress on Digestive
Video-endoscopy.
Padova (Italy), June 7-10, 1989.
19. **Guglietta, A.**, Nardi, R. V. and L.H. Lazarus
DOES A COMMON MECHANISM OF ACTION EXIST FOR CENTRALLY
ACTING GASTRIC INHIBITORY PEPTIDES ?
International Symposium on Brain-Gut
Interactions, Cambridge (U.K.), July 4-7, 1989.
Dig. Dis. Sci. 34 (6), 1989
20. **Guglietta, A.**, Hervada, T., and Nardi, R.V.
DYNAMICS OF EtOH AND INDOMETHACIN-INDUCED GASTRIC DAMAGE
EVALUATED BY COMPUTERIZED MORPHOMETRIC ANALYSIS AND ³H-
THYMIDINE ASSAY
American Gastroenterological Association.
Annual Meeting, Texas, May 13-16, 1990.

Curriculum Vitae – Antonio Guglietta, MD, PhD (cont.)

21. Hervada, T., **Guglietta, A.**, Nardi, R.V. and Brown, H.R.
GASTRIC LESIONS INDUCED BY TITANOCENE DICHLORIDE IN RATS.
American Gastroenterological Association.
Annual Meeting, Texas, May 13-16, 1990.

22. Lazarus, L.H., Salvadori, S., Toamatis, R., de Castiglione, R., Wilson, W.E., and **Guglietta, A.**
DERMORPHIN AND DELTORPHINS: NATURAL OPIOID PEPTIDES WITH HIGH AFFINITY AND SELECTIVITY FOR MU AND DELTA RECEPTORS.
North Carolina Society for Neuroscience,
Annual Meeting, Durham, NC May 16, 1990.

23. **Guglietta, A.** and R.V. Nardi
EFFECT OF PDGF-BB ON HEALING OF INDOMETHACIN-INDUCED GASTRIC LESIONS IN RATS.
1st European Tissue Repair Meetings, Oxford (UK)
Aug. 27-29, 1991.

24. Hamilton, M., **Guglietta, A.**, Collins, K., Gerrelts, M., Fergus, J. and Marks, J.
THE USE OF A ZYMARK ii ROBOT TO PERFORM AUTOMATIC TITRATION OF GASTRIC JUICE SAMPLES.
Internation Symposium on Laboratory Automation and Robotics. Oct 20-23, 1991, Boston (MA)

25. **Guglietta, A.** and Nardi, R.V.
PDGF-BB ACCELERATES HEALING OF INDOMETHACIN-INDUCED GASTRIC LESIONS IN RATS.
Gastroenterology, 102 (4 Pt. II) A77, 1992.

26. **Guglietta, A.** , Amarant, T., Parikh, I., Lesch, C. and Nardi, R.V.
EFFECT OF A PHARMACOLOGICAL ACTIVE FRAGMENT OF EGF ON GASTRIC ACID SECRETION IN RATS AND MONKEYS.
Gastroenterology, 102 (4 Pt. II), A 735 1992.

27. **Guglietta, A.**, Romano, M., Lesch, C., McClure, R.W., Coffey, R.J.
COMPARISON BETWEEN EGF AND TGF ON INHIBITION OF GASTRIC ACID SECRETION IN RATS AND MONKEYS.
Gastroenterology, 102 (4 pt. II), A736, 1992.

28. **Guglietta, A.**
POSSIBLE CLINICAL USE OF PEPTIDE GROWTH FACTORS IN THE GI TRACT: PERPECTIVES AND OBSTACLES.
3rd Symposium on experimental ulcer disease: Stress, Basic and Clinical Research-Gastrointestinal Protection. Zagreb, Croatia June 1-2, 1992
Exp. and Clin. Gastroenterology

Curriculum Vitae – Antonio Guglietta, MD, PhD (cont.)

29. **Guglietta, A.**, CA Lesch
EFFECT OF EGF AND PDGF ON EXPERIMENTALLY-INDUCED GASTRIC LESIONS
AND GASTRIC ACID SECRETION IN RATS AND MONKEYS.
3rd Congress of the International Brain-Gut Society, Florence, Italy, Nov. 19-21,
1992
30. **Guglietta A.**, Lesch, CA., Romano M., Coffey RJ.
TRANSFORMING GROWTH FACTOR ALPHA INHIBITS GASTRIC ACID
SECRETION IN RATS AND MONKEYS: COMPARISON WITH EPIDERMAL
GROWTH FACTOR.
Annual American Gastroenterological Association Meeting, Boston May 1993
Gastroenterology 104 (4), A828, 1993.
31. **Guglietta A.**, Lesch CA., Sanchez B.
PROTECTIVE AND HEALING EFFECT OF h-EGF 1-48 ON TNBS-INDUCED
COLONIC DAMAGE IN RATS: A MORPHOMETRIC EVALUATION.
II European Gastroenterology Week, Barcelona (Spain), July 19-24, 1993.
Gut 34 (3), S38, 1993.
32. **Guglietta A.**, Veljaca M, Lesch, C, Sanchez, B, Romano, M, Meise, KS, Coffey RJ
ROLE OF TGF ALPHA AND EGF IN THE ADAPTATION PHENOMENON
FOLLOWING REPEATED ADMINISTRATION OF ASPIRIN IN MONKEYS.
Croatian days of selected topics in medical sciences: 1) Ulcer disease and
gastrointestinal protection: experimental and clinical research. 2) Stress: basic and
clinical research, Zagreb, Nov. 19-21, 1993. Exp. and Clin. Gastroenterology:
1994 in press.
33. Veljaca, M, Pillana, R, Sancez, B, **Guglietta, A.**
EFFECT OF BPC ON TNBS-INDUCED COLONIC DAMAGE IN RATS.
Croatian days of selected topics in medical sciences: 1) Ulcer disease and
gastrointestinal protection: experimental and clinical research. 2) Stress: basic and
clinical research, Zagreb, Nov. 19-21, 1993. Exp. and Clin. Gastroenterology:
1994 in press.
34. Romano, M, **Guglietta, A**, M, Lesch, CA, Meise, KS, Veljaca, M, Sanchez, B,
Coffey, RJ.
ROLE OF TGF ALPHA AND EGF IN THE GASTRIC ADAPTATION TO ASPIRIN IN
MONKEYS AND RATS.
Annual American Gastroenterological Association Meeting, New Orleans, May
1994 Gastroenterology 106 (4 pt II) A836, 1994
35. Veljaca, M., Pillana, R., Lesch, CA., Sanchez, B., Chan, K., **Guglietta, A.**
PROTECTIVE EFFECT OF BPC 15 ON A RAT MODEL OF COLITIS.
Annual American Gastroenterological Association Meeting, New Orleans, May
1994 Gastroenterology 106 (4 pt II) A789, 1994
36. Veljaca, M., Pillana, R., Lesch, CA., Sanchez, B., K. Chan, **Guglietta, A.**
PROTECTIVE EFFECT OF BPC 15 ON A RAT MODEL OF COLITIS.
World Congress of Gastroenterology, Oct. 2-7, 1994, Los Angeles, CA, USA

Curriculum Vitae – Antonio Guglietta, MD, PhD (cont.)

37. M. Veljaca, C. Lesch, B. Sanchez, J. Low, **A. Guglietta**
 PROTECTION OF BPC-15 ON TNBS -INDUCED COLITIS IN RATS.
 POSSIBLE MECHANISM OF ACTION.
 Croatian days of selected topics in medicine: 5th International Symposium on GI Research:
 Experimental and Clinical Relevance, Zagreb (Cro) Nov. 2-4, 1994
 Exp. Clin. Gastroenterol.

38. **A. Guglietta.**
 PRECLINICAL EVALUATION OF COMPOUNDS WITH POSSIBLE THERAPEUTIC
 ACTIVITY IN INFLAMMATORY BOWEL DISEASE.
 Croatian days of selected topics in medicine: 5th International Symposium on GI Research:
 Experimental and Clinical Relevance, Zagreb (Cro) Nov. 2-4, 1994
 Exp. Clin. Gastroenterol.

39. M. Romano, **A. Guglietta**, CA Lesch, KS Meise, M. Veljaca, B. Sanchez, RJ Coffey
 TRANSFORMING GROWTH FACTOR ALPHA, BUT NOT EPIDERMAL GROWTH
 FACTOR, MAY PLAY A ROLE IN THE ADAPTATION OF GASTRIC MUCOSA TO
 REPEATED ADMINISTRATION OF ASPIRIN TO MONKEYS AND RATS.
 National conference on digestive diseases, Florence (Italy), Dec. 3-7, 1994.
 Italian J. Gastroenterol. 26 (9), S. 2, A141, 1994.

40. VM Baragi, Z. Gunja-Smith, JF Woessner, CA Lesch, **A. Guglietta**
 ROLE OF METALLOPROTEINASE IN THE DEVELOPMENT OF
 ACETIC-ACID INDUCED GASTRIC ULCER IN RATS.
 Annual American Gastroenterological Association Meeting, San Diego (CA), May
 1995 Gastroenterology 108 (4 Suppl.) A52, 1995.

41. M. Veljaca, CA Lesch, B. Sanchez, J. Low, **A. Guglietta.**
 PROTECTION OF BPC-15 ON TNBS-INDUCED COLITIS IN RATS:
 POSSIBLE MECHANISMS OF ACTION.
 Annual American Gastroenterological Association Meeting, San Diego (CA), May
 1995 Gastroenterology 108 (4 Suppl) A936, 1995.

42. M. Veljaca, K. Chan, **A. Guglietta**
 DIGESTION OF h-EGF, h-TGF α AND BPC-15 IN HUMAN GASTRIC JUICE.
 Annual American Gastroenterological Association Meeting, San Diego (CA), May
 1995 Gastroenterology 108 (4 Suppl) A761, 1995.

43. CA Lesch, **A. Guglietta**
 PD 153035, AN EGF RECEPTOR (EGFr) TYROSINE-KINASE SPECIFIC
 INHIBITOR, REVERSES THE EFFECT OF EGF ON GASTRIC SECRETION AND
 TNBS-INDUCED COLITIS IN RATS.
 Annual American Gastroenterological Association Meeting, San Diego (CA), May
 1995 Gastroenterology 108 (4 Suppl.) A735, 1995.

Curriculum Vitae – Antonio Guglietta, MD, PhD (cont.)

44. M. Veljaca, CA Lesch, B. Sanchez, J. Low, **A. Guglietta**
 PROTECTION OF BPC-15 ON THE TNBS-INDUCED COLITIS IN RATS:
 POSSIBLE MECHANISMS OF ACTION.
 EPHAR, First European Congress of Pharmacology, Milan (Italy) , June 16-19, 1995.
 Pharmacological Research, 31 (Suppl), 13, 1995.
45. M. Veljaca, K. Chan, **A. Guglietta**
 DIGESTION OF h-EGF ALPHA AND BPC-15 IN HUMAN GASTRIC JUICE
 EPHAR, First European Congress of Pharmacology, Milan (Italy) , June 16-19, 1995.
 Pharmacological Research, 31 (Suppl.), 70, 1995.
46. **A. Guglietta**, ER Kraus, B. Sanchez, CA Lesch
 PROTECTIVE EFFECT OF EGF ON IODOACETAMIDE MODEL OF COLITIS.
 Annual American Gastroenterological Association Meeting, San Francisco (CA), May
 1996. Gastroenterology 110 (4 Suppl.) A 919, 1996.
47. **A. Guglietta**, ER Kraus, B. Sanchez, CA Lesch.
 ROLE OF SENSORY NERVES IN ANIMAL MODELS OF COLITIS.
 Annual American Gastroenterological Association Meeting, San Francisco (CA), May
 1996. Gastroenterology 110 (4 Suppl.) A919, 1996.
48. Dyer RD, Bornemeier D., Doubleday R, Song Y., **Guglietta A.**
 Laemont K., Okonkwo G. Schrier D.
 A NOVEL CLASS OF SLOW-EQUILIBRATING, ORALLY ACTIVE PGHS-2
 INHIBITORS
 Inflammation Research Association meeting, Hershey (PA), USA, Oct.27-Oct.31, 1996
49. **A. Guglietta**
 ROLE AND POSSIBLE CLINICAL APPLICATIONS OF PEPTIDE GROWTH FACTORS IN
 INFLAMMATORY AND NON INFLAMMATORY GASTROINTESTINAL DISEASES.
 New Approaches to Pharmacotherapy for Hepatic and Gastrointestinal Ulcerative and
 Inflammatory Disorders, Sperlonga (Italy), Sept. 3-7, 1996.
 Dig. Dis. Sci. 42(1), 197, 1997
50. V. Baragi, **A. Guglietta**
 GENE THERAPY: A NEW APPROACH FOR TREATMENT OF GASTROINTESTINAL DISORDERS.
 New Approaches to Pharmacotherapy for Hepatic and Gastrointestinal Ulcerative and
 Inflammatory Disorders, Sperlonga (Italy), Sept. 3-7, 1996.
 Dig. Dis. Sci.: 42(1), 197, 1997
51. **A. Guglietta**, E.R. Kraus, B. Sanchez, C.A. Lesch
 ARE SENSORY NERVES INVOLVED IN ANIMAL MODELS OF COLITIS ?
 New Approaches to Pharmacotherapy for Hepatic and Gastrointestinal Ulcerative and
 Inflammatory Disorders, Sperlonga (Italy), Sept. 3-7, 1996.
 Dig. Dis. Sci.: 42(1), 211, 1997

Curriculum Vitae – Antonio Guglietta, MD, PhD (cont.)

52. **A. Guglietta**, E.R. Kraus, B. Sanchez, C.A. Lesch
EGF PROTECTS AGAINST IODACETAMIDE-INDUCED COLITIS IN RATS.
New Approaches to Pharmacotherapy for Hepatic and Gastrointestinal Ulcerative and Inflammatory Disorders, Sperlonga (Italy), Sept. 3-7, 1996.
Dig. Dis. Sci.: 42(1), 211, 1997
53. Y. Song, D.T. Connor, A.D. Sercel, R.J. Sorenson, R. Doubleday, P.C. Unangst, B.D. Roth, W. Cornell, R.B. Gilbertsen, K. Chan, D.J. Schrier, K. Laemont, G.C. Okonkwo, **A. Guglietta**, D.A. Bornemeier and R.D. Dyer.
SUBSTITUTED DI-T-BUTYLPHENOLS: A NEW CLASS OF POTENT AND SELECTIVE PGHS-2 INHIBITORS.
American Chemical Society meeting, San Francisco, CA, Apr. 13-17, 1997.
54. Y. Song, D.T. Connor, R. Doubleday, R.J. Sorenson, A.D. Sercel, P.C. Unangst, W. Cornell, R.B. Gilbertsen, K. Chan, D.J. Schrier, K. Laemont, G.C. Okonkwo, **A. Guglietta**, D.A. Bornemeier and R.D. Dyer.
NOVEL DI-T-BUTYLPHENOLS AS SELECTIVE PGHS-2 INHIBITORS AND ORALLY ACTIVE AND SAFE ANTI-INFLAMMATORY AGENTS.
American Chemical Society meeting, San Francisco, CA, Apr. 13-17, 1997.
55. A.D. Sercel, Y. Song, T. Belliotti, V.G. Beylin, D.T. Connor, M.E. Marlatt, R.J. Sorenson, P.C. Unangst, R.B. Gilbertsen, K. Chan, D.J. Schrier, K. Laemont, G.C. Okonkwo, **A. Guglietta**, D.A. Bornemeier and R.D. Dyer.
SAR STUDIES OF SUBSTITUTED DI-T-BUTYLPHENOLS AS SELECTIVE COX-2 INHIBITORS.
American Chemical Society meeting, San Francisco, CA, Apr. 13-17, 1997.
60. **A. Guglietta**, C.A. Lesch, E.K. Kraus, B. Sanchez.
EFFECT OF EGF-RECEPTOR LIGANDS ON TNBS COLITIS IN RATS
American Gastroenterological Association meeting, Washington DC, May 11-14, 1997
Gastroenterology, 112, 4, A988, 1997
61. **A. Guglietta**, C.A. Lesch, O. Kasali.
CORRELATION BETWEEN COMPUTERIZED MORPHOMETRIC ANALYSIS, MACROSCOPIC SCORE AND HISTOPATHOLOGY SCORE OF COLONIC LESIONS.
American Gastroenterological Association meeting, Washington DC, May 11-14, 1997
Gastroenterology, 112, 4, A379, 1997
62. **A. Guglietta**, C.A. Lesch, E.R. Kraus, B. Sanchez.
DO PGHS-2 INHIBITORS HAVE A BENEFICIAL EFFECT ON EXPERIMENTAL MODELS OF INFLAMMATORY BOWEL DISEASE ?
American Gastroenterological Association meeting, Washington DC, May 11-14, 1997
Gastroenterology, 112, 4, A988, 1997
63. **A. Guglietta**, C.A. Lesch, E.K. Kraus, B. Sanchez.
PD 137,968: A GASTROINTESTINAL-SAFE ANTI-INFLAMMATORY COMPOUND WITH BENEFICIAL ACTIVITY ON TNBS COLITIS.
American Gastroenterological Association meeting, Washington DC, May 11-14, 1997
Gastroenterology, 112, 4, A988, 1997

Curriculum Vitae – Antonio Guglietta, MD, PhD (cont.)

64. **A. Guglietta**, C.A. Lesch, E.K. Kraus, R. Dyer, D. Schrier, B. Sanchez.
EFFECT OF PGHS-2 INHIBITORS AND OTHER ANTI-INFLAMMATORY DRUGS ON
HEALING OF ACETIC ACID-INDUCED ULCER IN RATS.
American Gastroenterological Association meeting, Washington DC, May 11-14, 1997
Gastroenterology, 112, 4, A135, 1997
65. F. Lirussi, B. Sanchez, A. Beccarello, **A. Guglietta**
APOPTOSIS OF K562 CELLS INDUCED BY NATURAL KILLER (nk) CELLS. DETECTION BY A
NEW ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) METHOD
American Association for the Study of Liver Diseases, Chicago, USA, Nov. 7-11, 1997
Hepatology 26 (4 Pt.2), 550A, Abs # 1687, 1997.
66. F. Lirussi, B. Sanchez, L. Pellizzari, **A. Guglietta**
NATURAL KILLER (NK) CELLS IN PATIENTS WITH CHRONIC HEPATITIS C (CHC)
Asian Pacific Association for the Study of the Liver
Burswood, Perth, Australia, Feb. 16-20, 1998
Journal of Gastroenterology and Hepatology 13 (S), 1998
67. F. Lirussi, B. Sanchez, L. Pellizzari, **A. Guglietta**
NATURAL KILLER (NK) CELLS IN PATIENTS WITH CHRONIC HEPATITIS C (CHC)
The British Society of gastroenterology Annual Meeting, Harrogate, March 10-13, 1998
Gut 42 (S1), 1998
68. F. Lirussi, B. Sanchez, L. Pellizzari, **A. Guglietta**
NATURAL KILLER (NK) CELLS INPATIENTS WITH CHRONIC HEPATITIS C (CHC)
Europaen Ass. for the Study of Liver Meeting. Lisbon, Apr. 15-18, 1998.
Journal of Hepatology 28 (S1), 1998.
69. Sasa Periskic, Sven Seiwerth, Dan Yamini, **Antonio Guglietta**, Michael Stamos
EPIDERMAL GROWTH FACTOR IMMUNOSTAINING AS A PROGNOSTIC INDICATOR FOR
COLON CANCER
American Gastroenterological Association meeting, New Orleans, USA, May 16-22, 1998
Gastroenterology, 114, 4, G2730, 1998
70. C.A. Lesch, E.R. Kraus, **A. Guglietta**
THE GABA DERIVATIVE 3-ISOBUTYL-GABA (CI-1008) ACTS CENTRALLY TO PROTECT
AGAINST INDOMETHACIN-INDUCED GASTRIC DAMAGE IN RATS
American Gastroenterological Association meeting, New Orleans, USA, May 16-22, 1998
Gastroenterology, 114, 4, G0822, 1998
71. F. Lirussi, L. Pellizzari, C. Triches, B. Zalunardo, **A. Guglietta**, E. Mastropasqua.
HOST-RELATED AND VIRAL-RELATED FACTORS IN IFN TREATED CHRONIC HEPATITIS C
Infectious Pathogens in Gastrointestinal and Hepatic Disorders: Molecular Biology,
Pathogenesis and Therapeutic Implications. Vall de Nuria, Spain Sept 15th-19th, 1998
Dig. Dis. Sci. 44 (1), A21, 1999

Curriculum Vitae – Antonio Guglietta, MD, PhD (cont.)

72. A. Sallmani, M. Veljaca, D. Seveljevic-Jaran, CA Lesch, **A. Guglietta**
PENTAGASTRIN EXACERBATES TNBS-INDUCED COLONIC DAMAGE IN RATS.
American Gastroenterological Association meeting, Orlando, FL May 1999
Gastroenterology: 116 (4 Pt2), A838, G3641, 1999
73. M. Veljaca, D. Seveljevic-Jarn, A. Rogulja, Z. Ferencic, **A. Guglietta**.
EFFECT OF INTRACOLONIC ADMINISTRATION OF PL-10 ON TNBS-INDUCED COLONIC
DAMAGE IN RATS.
American Gastroenterological Association meeting, Orlando, FL May 1999
Gastroenterology: 116 (4 Pt.2), A838, G3640, 1999
74. C.A. Lesch, E.R. Kraus, **A. Guglietta**
THE GABA DERIVATIVE 3-ISOBUTYL GABA PROTECTS AGAINST INDOMETHACIN-INDUCED
GASTRIC DAMAGE IN RATS BY A CENTRAL MECHANISM INDEPENDENT OF GASTRIC
SECRETION OR PGE2 SYNTHESIS
International conference on Inflammopharmacology and Vith Symposium on Side-Effects of
Anti-Inflammatory Drugs, Braselton, GA, USA, May 23-26, 1999.,
Immunopharmacology 1999
75. A. Tabacco, M. Broccardo, **A. Guglietta**, G. Improta
CENTRAL EFFECT OF TWO NATURAL TACHYKININS, PGSPI AND PG-KII ON EXPERIMENTAL
COLITIS IN RATS
Italian society of Pharmacology meeting, Florence (Italy), Jun 21-23, 1999
76. M. Broccardo, **A. Guglietta**, G. Improta, A. Tabacco
EFFECT OF A NATURAL NK1 TACHYKININ RECEPTOR AGONIST, PGSPI ON TWO MODELS OF
EXPERIMENTAL COLITIS IN RATS
2nd European Congress of Pharmacology, Budapest, Hungary July 3-7, 1999
Fundamental & Clinical Pharmacology 13 (S1), 354s, 1999
77. D. Juilif, c. Lesch, B. Sanchez, **A. Guglietta**, J P Menetski
EXPRESSION OF PDE4B AND PDE4A IN INDOMETHACIN AND ACETIC ACID DAMAGED
GASTRIC TISSUE
Gordon Conference on Cyclic Nucleotide Phosphodiesterases
Waterville Valley resort, New Hampshire July, 1999
78. CA Lesch, B. Sanchez, **A. Guglietta**
DARBUFELONE DOES NOT DELAY HEALING OF PRE-EXISTING GASTRIC ULCER
4TH Parke- Davis Discovery Research Symposium
Ypsilanti, MI Oct. 15, 1999
- 79 CA Lesch, B. Sanchez, **A. Guglietta**
EFFECT OF DARBUFELONE ON ARACHIDONIC ACID METABOLITES SYNTHESIS IN THE
STOMACH AND PERIPHERAL INFLAMMATORY SITES
4TH Parke- Davis Discovery Research Symposium
Ypsilanti, MI Oct. 15, 1999
- 80 CA Lesch, B. Sanchez, H. Van Vliet, **A. Guglietta**
GABAPETINOIDS PROTECT AGAINST NSAID-INDUCED GASTRIC DAMAGE
4TH Parke- Davis Discovery Research Symposium
Ypsilanti, MI Oct. 15, 1999

81. **A. Guglietta**, CA Lesch, H. Van Vliet, B. Sanches, JL Abitbol
EFFECT OF DARBUFELONE ON ARACHIDONIC ACID METABOLITES SYNTHESIS IN THE
STOMACH AND PERIPHERAL SITES IN RATS
American Gastroenterological Association Meeting, May 21-24, San Diego, USA, 2000
Gastroenterology
82. G. Castiglione, F. Lirussi, **A. Guglietta**.
NATURAL KILLER (NK) CELL CYTOTOXICITY IN CHRONIC HCV INFECTION. RELATIONSHIP
WITH CLINICAL AND VIROLOGICAL FEATURES AND RESPONSE TO INTERFERON (IFN).
83. C. Albet, JA Perez, J Muñoz, M. Ortega, **A. Guglietta**
DETERMINATION OF ABAPERIDONE, A NEW ATYPICAL ANTIPSYCHOTIC IN HUMAN PLASMA
BY LC/MC
VI International Congress of Pharmaceutical Sciences "Updating and New Perspectives of
Analytical Method Validation", Barcelona 26th-28th March 2001.
84. A. Romero, F. Gomez, MT Grau, F. Villamayor, **A. Guglietta**
SUBACUTE TOXICITY OF OMILOXETINE IN RATS AND BEAGLE DOGS
VI International Congress of Pharmaceutical Sciences "Updating and New Perspectives of
Analytical Method Validation", Barcelona 26th-28th March 2001.
85. A. Romero, MT Grau, F. Villamayor, F. Gomez, L. Canut, J. Zapatero. **A. Guglietta**
EMBRYOTOXICITY OF ABAPERIDONE IN RATS AND RABBITS
VI International Congress of Pharmaceutical Sciences "Updating and New Perspectives of
Analytical Method Validation", Barcelona 26th-28th March 2001.
86. **A. Guglietta**
GROWTH FACTORS IN GASTROINTESTINAL DISORDERS
3rd Croatian Congress of Pharmacology, Zagreb (Croatia) Sept. 19-21, 2001
87. Veljaca M., D. Seveljevic-Jaran, A. Rogulia, K. Brajsa, **A. Guglietta**
TNBS-INDUCED COLITIS IN INTERFERON- γ KNOCK-OUT MICE
World Congress of Gastroenterology, Bangkok Feb 2002
88. Anglada L, Delgado M, Palacin C, Palomer A. and **Guglietta A.**
ASSIGNMENT OF ABSOLUTE CONFIGURATION OF (R)- AND (S)-SERTACONAZOLE
NITRATE
14th International Symposium on Chirality (ISCD-14, Chirality 2002), Hamburg Sept. 8-12,
2002
89. Albet C., Guerrero M., **Guglietta A.**, and Palomer A.
SECADO EN INDUSTRIAS FARMACEUTICAS Y BIOTECNOLÓGICAS
Symposium on "Deshidratación: procesos, estructura y funcionalidad", IBERDESH-2002
Valencia, Spain Sept. 25-27, 2002
90. Anglada, L., Delgado R., Princep M., Terencio J., **A. Guglietta**
3-PHENYL-THIAZOLO[3,2-a] PYRIMIDIN-5-ONES AS POTENTIAL ATYPICAL
ANTIPSYCHOTIC
13th European Symposium on organic chemistry
Cavtat, Croatia Sept. 10-15, 2003

91. Terencio J., Princep M., Perez, C., Buira, I., Palop, D., Romero, A., **A. Guglietta**
 PHARMACOLOGICAL PROFILE OF OMILOXETINE, A NEW SELECTIVE SEROTONIN REUPTAKE
 INHIBITOR (SSRI)
 33rd Annual Society for Neuroscience meeting
 New Orleans, USA, Nov. 8-12, 2003
92. Brasó, A., Princep, M., Schmid, M., **Guglietta, A.**
 Development Pharmacology: Behavioral Assays in Antipsychotic
 Abstract Spanish Society of Pharmacology, Cadiz, España 2003
 Methods and Findings
93. Mendéz. E., Alemany, C., Tarragó C., Martí N., Anglada, L., Palomer, A., Palacín C.,
 Terencio, J., **Guglietta, A.**
 Identificación of novel inhibitors of the YgbP, the third enzyme of the MEP pathway, using a
 biochemical HTS approach.
 45th Interscience conference on antimicrobial agents and chemotherapy (ICAAC), New
 Orleans, 2005
94. Piqué, M., González, M., Falcó, J.L., Buira, I., Méndez E., Terencio, J., Pérez C., Princep, M.,
 Palomer, A., **Guglietta A.**
 DESIGN, SYNTHESIS AND BIOLOGICAL ACTIVITY OF N-SUBSTITUTED 2-PHENYL-INDOLES
 AND BENZIMIDAZOLE AS POTENTIAL HYPNOTIC DRUGS.
 Joint Meeting on Medicinal Chemistry, Vienna June 20-23, 2005
95. Guerrero, M. Oliva M., Romero, A., Guglietta A., Pérez, P., Miñarro M., Suñe-Negre, J.M.,
 Ticó J.R.
 NEW COST-EFFECTIVE, ENVIRONMENTALLY BENIGN PREPARATION OF NANOPARTICLES.
 32nd Annual meeting & Exposition of the Controlled released Society, June 18-22, 2005,
 Miami (FL), USA
96. Cano, M., Delgado, M., Nieto, J., Anglada, L., Falcó, J.L., Sanchez, M., Alemany, C.,
 Palaciín, C., Tarragó, C., Martí, N., Terencio, J., Palomar, A. **Guglietta, A.**
 SYNTHESIS AND ANTIBACTERIAL ACTIVITY OF OXAZOLIDINONE DERIVATIVES
 9th International conference on the chemistry of antibiotics and other bioactive compounds.
 Arcachon (France), Sept. 25-29, 2005
97. Cano, M., Delgado, M., Nieto, J., Anglada, L., Falcó, J.L., Sanchez, M., Alemany, C., Palacín,
 C., Tarragó, C., Martí, N., Terencio, J., Palomar, A. and **Guglietta A.**
 DISCOVERY OF 5-SUBSTITUTED OXAZOLIDINONE ANTIBACTERIAL AGENTS WITH
 REDUCED ACTIVITY AGAINST MONOAMINE OXIDASE
 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
 San Francisco, USA Sep. 27-30, 2006
98. Gropper, S., Rojas, M.J., **Guglietta A.**, Rovira, S., Merino, M. Cebrecos, J.
 FOOD INTERACTION BIOAVAILABILITY STUDY OF A TORASEMIDE NEW FORMULATION (10
 MG PROLONGED RELEASE) AFTER A HIGH FAT CONTENT MEAL
 Congreso nacional de farmacología clínica, Tenerife, Canary Islands, Spain Oct.30th-Nov.
 2nd, 2006, Basic & Clin. Pharm. & Tox. 99 (S1), 2006

99. Gropper, S., Albet, C., **Guglietta, A.**, Antonijoan, R., Gich, I., Barbanoj, M.J.
SINGLE-DOSE, RANDOMIZED, CROSS-OVER, BIOAVAILABILITY PILOT CLINICAL TRIAL OF TORASEMIDE IMMEDIATE RELEASE COMPARED TO A NEW PROLONGED RELEASE FORMULATION OF TORASEMIDE
Congreso nacional de farmacología clínica, Tenerife, Canary Islands, Spain Oct.30th-Nov. 2nd, 2006, Basic & Clin. Pharm. & Tox. 99 (S1), 2006

100. Gropper, S., Rojas, M.J., **Guglietta, A.**, Pelagio, P., Antonijoan, R., Gich, I., Barbanoj, M.J.
SINGLE AND REPEATED-DOSE, RANDOMIZED, CROSS-OVER, BIOAVAILABILITY CLINICAL TRIAL OF TORASEMIDE IMMEDIATE RELEASE COMPARED TO A NEW PROLONGED RELEASE FORMULATION OF TORASEMIDE
Congreso nacional de farmacología clínica, Tenerife, Canary Islands, Spain Oct.30th-Nov. 2nd, 2006, Basic & Clin. Pharm. & Tox. 99 (S1), 2006

101. Tarragó, C. Gómez, F., Santos, B., Guerrero, M., Schmid, M., Albareda, N., Martin G., Centellas, M., Albet, C., Anglada L., Trallero, A., Torres, J., Palacín C., D' Aniello, F., **Guglietta A.**
IN VITRO AND IN VIVO ANTIBACTERIAL ACTIVITY OF GF-001001-00, A NEW NON-FLUORINATED QUINOLONE.
ICAAC 46th Annual Meeting, San Francisco, USA, Sept. 27-30, 2006

102. Roca-Cusachs, A., Aracil, J., Calvo, C., Vaquer, J.V., Laporta, F., Martorell, J., Sobrino, J., Adroer, R., Gropper, S., **Guglietta, A.**
TORASEMIDA DE LIBERACIÓN PROLONGADA VERSUS TORASEMIDA DE LIBERACIÓN INMEDIATA EN EL TRATAMIENTO DE LA HIPERTENSIÓN LIGERA O MODERADA
12^a Reunión nacional del SEH-LELHA, Sevilla, Spain, Mar. 6-9, 2007

103. Roca-Cusachs, A., Aracil, J., Calvo, C., Vaquer, J.V., Laporta, F., Martorell, J., Boldueva, S., Churina, S., Zhrazhesvsky, K., Pavlysh, E., Sherenkov, A., Rojas, M.J., de Catellar, R., Gropper, S., **Guglietta, A.**
TORASEMIDE PROLONGED RELEASE VERSUS ITS IMMEDIATE-RELEASE FORM IN PATIENTS WITH MILD TO MODERATE HYPERTENSION
Abstract of 17th European Meeting of Hypertension, Milan, Italy June 15-19, 2007

104. Princep, M., Palop, D., Presotto, C., Impagnatiello, F., Bolla, M., Guglietta, A.
PHARMACOLOGICAL ACTIVITY OF GF-015646-00, A NOVEL NITRIC OXIDE (NO)-DONATING ANTI-INFLAMMATORY COMPOUND FOR THE TREATMENT OF INFLAMMATORY SKIN CONDITIONS.
Abstract 21st World Congress of Dermatology, Sept. 30- Oct. 5, 2007, Buenos Aires, Argentina

105. Alcántara, AM.; Princep, M., Pérez, C., Terencio, J., Mendez, E., Buira, I., Anglada, L., Palomer, A., **Guglietta, A.**
CORRELATION BETWEEN IN VITRO AND IN VIVO TESTS IN THE PHARMACOLOGICAL SCREENING OF NEW POTENTIAL SEDATIVE-HYPNOTIC MOLECULES
Abstract 39th European Brain and Behaviour Society meeting, Sept. 15-19, 2007, Trieste, Italy

106. Romero A., Grau T., Albet, C., Schmid, M., Guerrero, M., Tarragó, C., D' Aniello, F., **Guglietta, A.**
NON CLINICAL SAFETY EVALUATION OF OZENOXACIN (GF-001001-00), A NOVEL NON-FLUORINATED QUINOLONE.
Abstract 47th ICAAC Interscience Conference on Antimicrobial Agents and Chemotherapy, 10-20 Sep, 2007, Chicago, USA

107. Sierra, J.M., Ortega, M., Vila, J., Tarragó, C., Albet, C., Palacín, C., Terencio, J., **Guglietta, A.**
DECREASED LINEZOLID UPTAKE IN AN IN-VITRO-SELECTED LINEZOLID-RESISTANT
STAPHYLOCOCCUS EPIDERMIS MUTANT

Abstract 47th ICAAC Interscience Conference on Antimicrobial Agents and Chemotherapy, 10-20 Sep, 2007, Chicago, USA

108. Santos, B., D'Aniello, F., Tabernero, A., Albet, C., Tarragó, C., Orriols, A., Romero, A., **Guglietta, A.**
PRECLINICAL IN-VITRO AND IN-VIVO ABSORPTION OF OZENOXACIN (GF-001001-00) A NOVEL NON-
FLUORINATED QUINOLONE

Abstract 47th ICAAC Interscience Conference on Antimicrobial Agents and Chemotherapy, 10-20 Sep, 2007, Chicago, USA

109. Albareda, N., Gropper, S., Santos, B., Centellas, M., Tarragó, C., **Guglietta, A.**

OZENOXACIN (GF-001001-00) 1% OINTMENT FORMULATION: A PHASE I OPEN LABEL, SINGLE
RISING DOSE, PARALLEL GROUP STUDY TO EXAMINE THE SYSTEMIC BIOAVAILABILITY OF
TOPICAL APPLICATION IN HEALTHY VOLUNTEERS

Abstract 47th ICAAC Interscience Conference on Antimicrobial Agents and Chemotherapy, 10-20 Sep, 2007, Chicago, USA

110. B. Santos, A. Tabernero, F. Villamayor, C. Albet, C. Tarragó, **A. Guglietta**

OZENOXACIN (GF-001001-00) IS NOT ABSORBED IN 1% AND 2% CREAM FORMULATIONS. A
PRECLINICAL IN-VITRO AND IN VIVO STUDY

49th ICAAC, San Francisco, CA, Sept. 12-15, 2009 (Submitted)

111. B. Santos, JL Falcó, N. Martí, **A. Guglietta**

AROMATASE Inhibition: An important role in the safety of azoles

49th ICAAC, San Francisco, CA, Sept. 12-15, 2009 (Submitted)

112. N. Albareda, S. Gropper, G. Martín, B. Santos, C. Tarrago, **A. Guglietta**

OZENOXACIN (GF-001001-00) 2% CREAM FORMULATION IS NOT ABSORBED. A PHASE I,
DOUBLE BLIND, 2 WAY CROSSOVER, PLACEBO CONTROLLED, MULTIPLE DOSE STUDY TO
EXAMINE THE SYSTEMIC BIOAVAILABILITY AND SAFETY OF TOPICAL APPLICATIONS IN
HEALTHY VOLUNTEERS

49th ICAAC, San Francisco, CA, Sept. 12-15, 2009 (Submitted)

113. C. Tarragó, D. Palop, F. D' Aniello, **A. Guglietta**

OZENOXACIN (GF-001001-00): In vitro and in vivo antibacterial activity

49th ICAAC, San Francisco, CA, Sept. 12-15, 2009 (Submitted)

114. J. González, M. Schmid, F. Villamayor, C. Tarragó, D. Gargallo, **A. Guglietta**

OZENOXACIN (GF-001001-00): In vivo termal and ocular tolerante and sensitization potential

49th ICAAC, San Francisco, CA, Sept. 12-15, 2009 (Submitted)

115. Jorge González, M. Schmid, C. Tarragó, D. Gargallo, A. Guglietta

OZENOXACIN (GF-001001-00): Non-clinical safety pharmacology and genotoxic evaluations

49th ICAAC, San Francisco, CA, Sept. 12-15, 2009 (Submitted)

116. N. Martí, C. Tarragó, D. Palop, M. Delgado, **A. Guglietta**

Biological characterization of the antimicrobial activity of arasertaconazole nitrate

49th ICAAC, San Francisco, CA, Sept. 12-15, 2009 (Submitted)

117. I. Morrissey, K. Maher, C. Tarragó, **A. Guglietta**
THE ACTIVITY OF OZENOXACIN (GF-001001-00) AGAINST GRAM-POSITIVE BACTERIA (GPB)
THAT CAUSE SKIN AND SOFT TISSUE INFECTION (SSTI)
49th ICAAC, San Francisco, CA, Sept. 12-15, 2009 (Submitted)

118. I. Morrissey, K. Maher, C. Tarragó, **A. Guglietta**
THE SPECTRUM OF ACTIVITY OF OZENOXACION (GF-001001-00)
49th ICAAC, San Francisco, CA, Sept. 12-15, 2009 (Submitted)

119. I. Morrissey, K. Maher, C. Tarragó, **A. Guglietta**
THE ACTIVITY OF OZENOXACIN (GF-001001-00) AGAINST ATYPICAL BACTERIA
49th ICAAC, San Francisco, CA, Sept. 12-15, 2009 (Submitted)

120. P.J. Stienen, C. Pérez, A.M. Alcántara, F. D' Aniello, L. Horosok, A.G. Fernández, AG, **A. Guglietta**
CNS PHARMACOLOGY OF A NOVEL NON-BENZODIAZEPINE HYPNOTIC, GF-015535-00, FOR THE
TREATMENT OF INSOMNIA
Neuroscience 2010, Nov. 13-17, San Diego, USA

121. B. Castro, V. Soto, M. Nicolás, A. Herrero, I. Gartzia, M. Montes, M. del Olmo, A.G.
Fernandez, **A. Guglietta**
A NOVEL CELL THERAPY FOR CARTILAGE REGENERATION BASED ON ADIPOSE MESENCHIMAL
STEM CELLS AND A NEW BIOMATERIAL OF NATURAL ORIGIN
Intl. Cartilage Repair Society (ICRS) meeting 2010, Sitges, Spain, Sept. 26-29, 2010

122. N. Martí, C. Tarragó, D. Palop, M. Delgado, **A. Guglietta**
ARASERTACONAZOL NITRATE: CHARACTERIZATION OF ANTIMICROBIAL ACTIVITY.
Eur. Society for Infectious Diseases in Obstetrics and Gynecology. Trieste, Italy, Oct.3-5, 2010

Curriculum Vitae - Antonio Guglietta, MD, PhD (cont.)

Chapters in books

Nardi, R.V., **Guglietta, A.** and Parikh, I.
 EPIDERMAL GROWTH FACTOR
 In: Handbook of Experimental Pharmacology, Vol. 99: pp. 37-54
 "Pharmacology of Peptic Ulcer Disease"
 Editors: Stanley Benjamin and Martin Collen
 Publisher: Springer-Verlag 1991

A. Guglietta, M. Veljaca
 Peptide Growth Factors in Gastrointestinal Disorder Therapeutics
 In: Drug Development: Molecular Targets for Gastrointestinal Diseases. (A Guglietta, TS
 Gagarella eds). Humana press, Totowa NJ, USA, pp 89-112, 1999.

Books edited

A. Guglietta, T.S. Gagarella (Eds.)
 Drug Development: Molecular Targets for GI Diseases
 Humana Press, Totowa, NJ, USA, 1999

A. Guglietta, F. Lirussi (Eds)
 Infectious pathogens in gastrointestinal and hepatic disorders
 Prous Science, Barcelona, Spain 1999

A. Guglietta (Ed.)
 Inflammatory and ulcerative conditions of the gastrointestinal tract:
 pathogenesis, prevention and treatment
 Current Pharmaceutical Design vol 7 N.1, Jan 2001

A. Guglietta (Ed.)
 Pharmacotherapy of Gastrointestinal Inflammation
 Birkhauser Publishers Ltd, Basel, Switzerland 2003

Curriculum Vitae – Antonio Guglietta, MD, PhD (cont.)

Patents

1) R. V. Nardi, T. Amarant, **A. Guglietta**
and Indu Parikh (1990).

GROWTH FACTORS COMPOSITIONS, PREPARATION AND USE.

United States and Foreign

US patent #: 5,434,135 issued Jul. 18, 1995

2) **A. Guglietta**, C.A. Lesch, G. Kraus.

TREATMENT OF INFLAMMATORY BOWEL DISEASE USING HISTAMINE H3 RECEPTOR AGONISTS

United States and Foreign patent. Serial # 09/416,158. Issued Feb. 22, 2000

3) **A. Guglietta** et al.

GABA ANALOGS TO PREVENT AND TREAT GASTROINTESTINAL DAMAGE

US patent #: 6,127,418 Issued Oct.3, 2000

4) Foguet, R., Ramentol, J., Anglada, J. Palacín, C., **Guglietta, A.**

R-(-)-1-[2-(7-CHLOROBENZO[B]THIOPHEN-3-YL-METHOXY)-2-(2,4-DICHLOROPHENYL)-ETHYL]-1H-IMIDAZOLE.

11 Feb 2002 – 200200328. Status depending on country

5) Foguet, R., Ramentol, J., Palacín, C., Guerrero, M., Raga, M. Romero, A., **Guglietta, A.**

PHARMACEUTICAL COMPOSITIONS OF SERTACONAZOLE FOR VAGINAL USE.

18 Dec 2002 - PCT/EP02/14488. Status depending on country.

6) Anglada, L, Palomer, A., Princep, M., **Guglietta, A.**

7-SUBSTITUTED 3-NITRO-PYRAZOLO[1,5-A]PYRIMIDINES AND COMPOSITIONS AND METHODS RELATED THERETO

24 Jul 2003 – 200301747. Pending

7) Anglada, L, Palomer, A., Princep, M., **Guglietta, A.**

N-[3-(3-SUBSTITUTED-PYRAZOLO[1,5-A]PYRIMIDIN-7-YL)PHENYL]-SULFONAMIDES, AND COMPOSITIONS AND METHODS RELATED THERETO.

24 Jul 2003 – 200301746. Pending

8) Guerrero, M. Romero, A., **Guglietta, A.**

PROLONGED-RELEASE DIURETIC COMPOSITIONS.

25 Mar 2004 – 200400740. Pending (Granted in Spain)

9) Guerrero, M., Orriols, A., Raga, M., **Guglietta, A.**

HYPOCHOLESTEROLEMIC COMPOSITIONS.

03 Feb 2004 - EP04002317.8. Pending

10) Cano, M., Palomer, A., **Guglietta, A.**

OXAZOLIDINONE COMPOUNDS AND COMPOSITIONS AND METHODS RELATED THERETO.

29 Jul 2004 - EP04103657.5. Pending

Curriculum Vitae – Antonio Guglietta, MD, PhD (cont.)

11) Falcó, J. L., Palomer, A., Guglietta, A.

IMIDAZO[1,2-A]PYRIDINE COMPOUNDS, COMPOSITIONS, USES AND METHODS related thereto. 11 Nov 2004 - EP04105698.7. Pending

12) Anglada, L., Palomer, A., Guglietta, A.

N-[3-(8-SUBSTITUTED-IMIDAZO[1,5-A]PYRIMIDIN-4-YL)-PHENYL-SULFONAMIDES, N-[3-(8-SUBSTITUTED-IMIDAZO[1,5-A]PYRIMIDIN-4-YL)-PHENYL]-CARBOXAMIDES, COMPOSITIONS, AND METHODS RELATED THERETO.

10 Feb 2005 - EP05100941.3. Pending

13) Raga, M., Sallarés, J., Guerrero, M., Guglietta, A.

NEW SALT OF 1-[3-[3-CHLOROPHENYL]PROPOXY]PROPYL]-PIPERIDINE.

10 Feb 2005 - EP05100942.1. Pending

14) Palacín, C., Guerrero, M., Torres, J., Raga, M., Guglietta, A.

ANTIFUNGAL COMPOSITIONS.

01 Mar 2005 - EP05101540.2. Pending

15) Miralles, R., Nonell, S., Teixidó, J., Raga, M., Guglietta, A.

BENZOIC ACID ESTER COMPOUNDS, COMPOSITIONS, USES AND METHODS.

21 Mar 2005 - EP05102228.3. Pending

16) Terencio, J., León, R., Villarroya, M., Guglietta, A.

DERIVADOS DEL ÁCIDO 5-AMINO-1,4-DIHIDRO[1,8]NAFTIRIDIN-3-CARBOXÍLICO.

25 May 2005 - 200501266. Pending

17) Cano, M., Palomer, A., Guglietta, A.

OXAZOLIDINONE COMPOUNDS, AND COMPOSITIONS AND METHODS RELATED THERETO.

27 Jun 2005 - EP05105714.9. Pending

18) Anglada, L., Palomer, A., Guglietta, A.

HALOGENATED PYRAZOLO[1,5-A]PYRIMIDINES, PROCESSES, USES, COMPOSITIONS AND INTERMEDIATES.

21 Jun 2005 - EP05105478.1, US 692866. Pending

19) Benedini, F., Ongini, E., Palop, D., Princep, M., Guglietta, A.

STEROID NITROOXYDERIVATIVES.

02 Sep 2005 - EP05019155. Pending

20) Falcó, J. L., Palomer, A., Guglietta, A.

IMIDAZO[1,2-A]PYRIDIN-3-YL-ACETIC ACID HYDRAZIDES, PROCESSES, USES AND COMPOSITIONS. 03 Jan 2006 - EP06100030. Pending

21) Falcó, J. L., Palomer, A., Guglietta, A.

IMIDAZO[1,2-B]PYRIDAZINES, PROCESSES, USES, INTERMEDIATES AND COMPOSITIONS.

29 Mar 2006 - EP06111899. Pending

Curriculum Vitae – Antonio Guglietta, MD, PhD (cont.)

22) Orriols, A., Guerrero, M., **Guglietta, A.**

COMPRIMIDO BICAPA PARA LA PREVENCIÓN DE LOS ACCIDENTES
CARDIOVASCULARES.

24 May 2006 - P200601355. Pending

23) Anglada, L., Palomer, A., **Guglietta, A.**

PYRAZOLO[1,5-A]PYRIMIDINES, PROCESSES, USES AND COMPOSITIONS.

4 Ago 2006, EP06118454.5. Pending

24) Falcó, J. L., Palomer, A., **Guglietta, A.**

1H-QUINOLIN-4-ONE COMPOUNDS, PROCESSES, USES AND COMPOSITIONS.

Submitted.

Other:

Organizer and co-chairman of the symposium "New Approaches to Pharmacotherapy for Hepatic and Gastrointestinal Ulcerative and Inflammatory Disorders", Sperlonga (Italy), Sept. 3-7, 1996.

Organizer and co-chairman of the symposium " Infectious pathogens in gastrointestinal and hepatic disorders", Vall de Nuria, Spain Sept. 15-19, 1998